SEOUL -- Samsung Bioepis will soon debut a biosimilar alternative to a top-selling breast cancer drug in Europe, marking a step forward for the Samsung conglomerate's pharmaceutical operations.
Produced by biological processes, biosimilars have nearly the same effect as existing pharmaceuticals but unlike generics, are not exact copies.
